Dian Diagnostics Group Co.,Ltd.'s Equity Buyback announced on December 7, 2022, has expired with 1,918,600 shares, representing 0.31% for CNY 49.99 million.
February 26, 2023
Share
The company expired its plan on February 27, 2023.
Dean Diagnostic Technology Group Co., Ltd. is a company providing integrated solutions for medical diagnosis. The Company's main business involves inspection services, product services, health management, judicial expertise, contract research organization (CRO), cold chain logistics and other fields. The Company's business is mainly oriented to medical and health institutions at all levels, such as various general and specialized hospitals, community health service centers, township (town) health centers, physical examination centers, disease prevention and control centers, etc. The Company's products include Atomic Bomb in the field of liquid phase mass spectrometry, Hydrogen Bomb in the field of nucleic acid mass spectrometry, and Man-Made Satellite in the field of pathological diagnosis products and molecular diagnosis products, and others.
Dian Diagnostics Group Co.,Ltd.'s Equity Buyback announced on December 7, 2022, has expired with 1,918,600 shares, representing 0.31% for CNY 49.99 million.